Registry-only trials were assessed as unclear risk of bias, as critical JBI domains, such as completeness of outcome data, appropriateness of analysis, and selective reporting, cannot be evaluated without peer-reviewed results
CBT-I has also shown effectiveness across various age groups
provides more modest weight loss (510%) with significant gastrointestinal side effects Each alternative carries distinct benefits, risks, and efficacy profiles requiring individualized discussion with healthcare providers
Any decision to prescribe, dose, or continue therapy is made by the licensed clinician based on the patient's medical profile
Therefore, taking a dose less than the recommended one may not provide optimal results
F.Van KogelenbergM.et al (2015)